Lacrimal gland Alterations and the Effect of artesunate on experimental induced diabetes rat models and related mechanisms

Girju Rajbanshi,Wei Li,Xiaolin Nong,Yi Li,Dongxiao Nong
DOI: https://doi.org/10.1038/s41598-024-61550-0
IF: 4.6
2024-06-01
Scientific Reports
Abstract:Diabetic patients are at high risk of developing lacrimal gland dysfunction, and the antimalarial drug artesunate (ART) was recently used to induce experimental-induced diabetes mellitus. This study's objective is to investigate the lacrimal gland alteration and the effect of ART on experimentally induced diabetes rat models and its related mechanisms. Forty rats were divided into five groups (8 rats/group): healthy control group (HC), diabetic group (DM), 50 mg/kg ART intervention diabetic group [DM + ART (50 mg/kg)], 100 mg/kg ART intervention diabetic group [DM + ART (100 mg/kg)] and 6 U/kg Insulin intervention diabetic group (DM + INS). The morphology of the eyeball and lacrimal gland tissues was determined using hematoxylin and eosin staining. In addition, external lacrimal glands were harvested for electronic microscopic examination, NFκB1, and TNF-α protein expression evaluation by immunohistochemistry and mRNA expression analysis by RT-PCR. Histopathological and ultrastructural changes suggest ART intervention has an improved structural effect. Protein expression of NFκB1 in the DM + ART (100 mg/kg) group was decreased. TNF-α significantly decreased in the DM + ART (50 mg/kg) and insulin groups. We concluded that ART improves structural changes in a lacrimal gland in diabetic rats. The present study provides further evidence of the therapeutic effect of ART on the lacrimal gland of diabetic rats by decreasing the expression of NFκB1 and TNF-α.
multidisciplinary sciences
What problem does this paper attempt to address?
The problem that this paper attempts to solve is lacrimal gland dysfunction caused by diabetes and its related mechanisms, and to explore the effect of the antimalarial drug artesunate (ART) on the structure and function of the lacrimal gland in an experimentally - induced diabetic rat model. Specifically, the study aims to evaluate whether ART can improve the structural changes of the lacrimal gland in diabetic rats, reduce the expression of inflammatory markers NF - κB1 and TNF - α, and thus alleviate dry eye symptoms. ### Research Background - **Diabetes and Ocular Complications**: Diabetic patients are prone to various ocular complications, such as diabetic retinopathy, glaucoma, cataract, etc. Among them, dry eye syndrome (DES) is a common problem that seriously affects the quality of life. - **Pathological Mechanisms of Dry Eye**: Factors such as hyperglycemia, oxidative stress, nerve damage and insulin dysfunction caused by diabetes may lead to lacrimal gland dysfunction, which in turn leads to dry eye. - **The Role of Artesunate**: Artesunate is an antimalarial drug extracted from the plant Artemisia annua, which has multiple biological activities such as anti - inflammatory, antioxidant and hypoglycemic. Studies have found that artesunate can inhibit the NF - κB - mediated inflammatory signaling pathway, reduce blood glucose levels, and protect pancreatic islet cells. ### Research Objectives - **Evaluate the Effect of Artesunate on the Lacrimal Gland of Diabetic Rats**: Through an experimentally - induced diabetic rat model, study the improvement effect of artesunate on the structure and function of the lacrimal gland. - **Explore the Mechanism of Action of Artesunate**: Analyze the effect of artesunate on the expression of NF - κB1 and TNF - α, and reveal its potential therapeutic mechanism. ### Experimental Design - **Animal Grouping**: 40 rats were divided into 5 groups, with 8 rats in each group: - Healthy control group (HC) - Diabetic group (DM) - Artesunate - intervened diabetic groups (DM + ART 50 mg/kg and DM + ART 100 mg/kg) - Insulin - intervened diabetic group (DM + INS 6 U/kg) - **Detection Indicators**: - Blood glucose level and body weight monitoring - Determination of tear secretion volume - Lacrimal gland weight and lacrimal gland weight/body weight ratio - Morphological examination of eyeball and lacrimal gland tissues (HE staining, electron microscope) - NF - κB1 and TNF - α protein expression (immunohistochemistry) - NF - κB1 and TNF - α mRNA expression (RT - PCR) ### Main Results - **Blood Glucose and Body Weight**: The blood glucose level in the diabetic group increased significantly, and the body weight increased slowly. The changes in blood glucose level and body weight in the artesunate and insulin - intervened groups were similar to those in the diabetic group, but the body weight in the artesunate - intervened group increased more slowly. - **Tear Secretion**: The tear secretion volume in the diabetic group decreased significantly, while the tear secretion volume in the artesunate - intervened group (especially in the 100 mg/kg dose group) increased. - **Lacrimal Gland Structure**: The lacrimal gland in the diabetic group showed atrophy and fibrosis, and the lacrimal gland structure in the artesunate - intervened group was improved, and lymphocyte infiltration was reduced. - **NF - κB1 and TNF - α Expression**: The expression of NF - κB1 and TNF - α in the diabetic group increased significantly, while the expression levels in the artesunate - intervened group decreased, especially in the 100 mg/kg dose group. ### Conclusions - **Artesunate Improves the Lacrimal Gland Function of Diabetic Rats**: Artesunate can improve the structural changes of the lacrimal gland in diabetic rats, reduce the expression of inflammatory markers NF - κB1 and TNF - α, and thus alleviate dry eye symptoms. - **Potential Mechanism**: Artesunate reduces the inflammatory response and protects the lacrimal gland function by inhibiting the NF - κB - mediated inflammatory signaling pathway. ### Significance - **Clinical Application Prospects**: This study provides new evidence for artesunate in the treatment of dry eye caused by diabetes, and more effective treatment regimens may be developed in the future. - **Further Research Directions**: More clinical trials are needed to verify the efficacy and safety of artesunate in human diabetic patients.